NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Charite University, Berlin, Germany
Conditions: Atopic Dermatitis
Interventions: not applicable, observational study
Countries: Germany
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.
Sex: ALL
Age: 18 Years to 75 Years
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Age 18 and above * Diagnosis of atopic dermatitis for ≥1 year * Inadequate response to treatment with topical medications * Confirmed dupilumab treatment Exclusion Criteria: * Age below 18 * Known or suspected allergy or reaction to any component of the dupilumab formulation * Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of the severity of AD * Severe conjunctivitis or blepharitis
- Berlin, Germany